NANETS Regional NET Education: The Multidisciplinary Management of NET Disease

May 7, 2022

8:15am – 3:00pm 

Earn up to 5.5 AMA PRA Category 1 Credits,™ Continuing Nursing Education (ANCC), and MOC accreditation

Register Here


Chicago Marriott Downtown Magnificent Mile
540 Michigan Ave.
Chicago, IL 60611

NANETS does not facilitate a Group Room Block for Regional Conferences, all hotel rooms are book on own.


Jointly Provided by the University of Chicago Medicine and the North American Neuroendocrine Tumor Society

Course Director

Xavier Keutgen, MD, and Chih-Yi "Andy" Liao, MD, University Chicago Medicine


Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has dramatically increased over the last ten years, including within the Chicagoland area. As this is a rare disease and since the diagnostic and therapeutic landscape has significantly changed over the past decades, clinicians can sometimes struggle to set up a multidisciplinary long-term care plan for their NET patients. During this symposium we will therefore review all aspects of specialized NET care and present unique tips and tricks on how to treat these complex patients. Moreover, we will have two keynote lectures from other NANETS members regarding the future of systemic NET therapy and familial syndromes associated with NETs.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
  • Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
  • Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
  • Recognize the clinical features associated with carcinoid syndrome
  • Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
  • Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors


8:15-8:45 am     Registration & Breakfast

8:45-9:00 am     Welcome and Opening Remarks

9:00-9:45 am     Overview of Neuroendocrine Tumors

Tanaz Vaghaiwalla, MD; University of Tennessee Medical Center and Namrata Setia, MD; University of Chicago Medicine

  • Background, Epidemiology, et
  • Imaging for Diagnosis & follow etc (what is the role of GaDOTATATE in Dx and F/U?)
  • Endoscopic diagnosis etc
  • Path of NETs: General features, etc

9:45-10:20 am  Surgical Management of NETs

Xavier M Keutgen, MD; University of Chicago Medicine

  • Intraop management: Octreotide etc
  • Surgical principles in SBNETs:
  • Surgical principles in PNETs
  • Surgery for gastric, duodenal, etc
  • Principles of Hepatic etc

10:20-10:30 am   Break

10:30-11:15 am  Current and Future Radiolabeled Therapies for NETs

Courtney Lawhn Heath, MD; University of California San Francisco

  • TBD
  • TBD

11:15-12:00 pm    Medical Management of NETs

Chih-Yi "Andy" Liao, MD; University of Chicago Medicine

  • Overview of Clinical Trials etc
  • Treatment of Progressive etc
  • Pepitide radioreceptor therapy to include GaDOTATAE as imaging for PRRT; Discussion of PRRT; Practical aspects of PRRT set up 

12:00-12:15 pm    Q&A | Morning Wrap Up

Tanaz Vaghaiwalla, MD;  Namrata Setia, MD; Xavier M Keutgen, MD; Courtney Lawhn Heath, MD and Chih-Yi "Andy" Liao, MD

12:15-1:00 pm    Lunch

1:00-1:30 pm      Management of Carcinoid Symptoms and Heart Disease

Thorvardur (Thor) R. Halfdanarson, MD; Mayo Clinic

  • TBD
  • TBD

1:30-2:00 pm     IR-Guided Liver-Directed Therapies

Divya Kumari, MD; University of Chicago Medicine

  • TBD
  • TBD

2:00-2:45 pm    Multi-D Tumor Board (3 case presentations)

Tanaz Vaghaiwalla, MD; Xavier M Keutgen, MD; Courtney Lawhn Heath, MD; Thorvardur (Thor) R. Halfdanarson, MD and Divya Kumari, MD

Moderated by Chih-Yi "Andy" Liao, MD

  • TBD
  • TBD

2:45 – 3:00 pm   Closing Remarks, Feedback and Adjourn


This continuing education activity is provided through collaboration between the North American Endocrine Tumor Society (NANETS) and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurse practitioners, and nurses. A statement of participation is available for other attendees.

Physicians, Physician Assistants, and Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians for ABIM Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation enables the participant to earn up to 5.5 Medical Knowledge only MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Use of Learner/Participant Data

Participation information will be shared with the applicable certifying board via ACCME PARS.

In order for MOC credit to be reported, evaluations must be completed prior to the close of evaluations.


Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and NANETS. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 5.5 hours of continuing nursing education credit.


In-person registration is available onsite the day of the program and will be accommodated on a space-available basis

Registration fee:


$65 - MD, PharmD, Doctoral Level 
$35 - Allied Health
Complimentary - Student/Fellow/Resident


$95 - MD, PharmD, Doctoral Level 
$50 - Allied Health
Complimentary - Student/Fellow/Resident

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before May 10, 2020. On or after May 11, 2020, no refund will be made.

The University Chicago Medicine and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is canceled, liability is limited to the registration fee.


Please contact us with any questions.